CCCC (C4 Therapeutics) Total Liabilities: $112.14 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCCC C4 Therapeutics Inc CCCC
49 GF Score
Price $4.12
GF Value $2.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is C4 Therapeutics Total Liabilities?

C4 Therapeutics CCCC +2.50% 49 Total Liabilities is $112.14 Mil as of Jun. 2026. GuruFocus rates CCCC with a GF Score™ of 49/100 and a GF Value™ of $2.05 (Significantly Overvalued). The stock has 7 warning signs investors should review.

C4 Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was $112.14 Mil.

C4 Therapeutics's quarterly Total Liabilities declined from Dec. 2025 ($102.49 Mil) to Mar. 2026 ($94.61 Mil) but then increased from Mar. 2026 ($94.61 Mil) to Jun. 2026 ($112.14 Mil).

C4 Therapeutics's annual Total Liabilities increased from Dec. 2023 ($130.34 Mil) to Dec. 2024 ($133.62 Mil) but then declined from Dec. 2024 ($133.62 Mil) to Dec. 2025 ($102.49 Mil).

C4 Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for C4 Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C4 Therapeutics Total Liabilities Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 117.16 141.61 130.34 133.62 102.49

C4 Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.46 111.08 102.49 94.61 112.14
CCCC
49GF Score
C4 Therapeutics Inc CCCC
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C4 Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

C4 Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.032+(53.615+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+15.841+0+0)
=102.49

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=359.075-256.587
=102.49

C4 Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=48.247+(50.178+-1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+13.714+0+0)
=112.14

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=359.404-247.265
=112.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $112.14 Mil mean?
C4 Therapeutics (CCCC) has a Total Liabilities of $112.14 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for C4 Therapeutics and its competitors.
Is C4 Therapeutics' Total Liabilities too high?
C4 Therapeutics' current Total Liabilities is $112.14 Mil. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' Total Liabilities compare to CMPX and AVIR?
C4 Therapeutics' Total Liabilities of $112.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for C4 Therapeutics and its competitors. C4 Therapeutics's current Total Liabilities is $112.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current Total Liabilities is $112.14 Mil. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current Total Liabilities is $112.14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C4 Therapeutics (CCCC) Overvalued in 2026?

Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued. The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05. GuruFocus considers C4 Therapeutics to be Significantly Overvalued.

Key valuation signals for CCCC:

  • Total Liabilities: $112.14 Mil
  • GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C4 Therapeutics Business Description

Address 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score

Get the complete analysis for CCCC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$2.05
GF Value